000840658 001__ 840658
000840658 005__ 20220930130138.0
000840658 0247_ $$2doi$$a10.1038/s41598-017-16565-1
000840658 0247_ $$2Handle$$a2128/17607
000840658 0247_ $$2WOS$$aWOS:000416135000074
000840658 0247_ $$2altmetric$$aaltmetric:29369476
000840658 0247_ $$2pmid$$apmid:29176708
000840658 037__ $$aFZJ-2017-08159
000840658 041__ $$aEnglish
000840658 082__ $$a000
000840658 1001_ $$00000-0002-1861-7530$$avan Groen, Thomas$$b0$$eCorresponding author
000840658 245__ $$aThe Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology
000840658 260__ $$aLondon$$bNature Publishing Group$$c2017
000840658 3367_ $$2DRIVER$$aarticle
000840658 3367_ $$2DataCite$$aOutput Types/Journal article
000840658 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1520841620_25958
000840658 3367_ $$2BibTeX$$aARTICLE
000840658 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000840658 3367_ $$00$$2EndNote$$aJournal Article
000840658 520__ $$aWhile amyloid-β protein (Aβ) aggregation into insoluble plaques is one of the pathological hallmarks of Alzheimer’s disease (AD), soluble oligomeric Aβ has been hypothesized to be responsible for synapse damage, neurodegeneration, learning, and memory deficits in AD. Here, we investigate the in vitro and in vivo efficacy of the d-enantiomeric peptide RD2, a rationally designed derivative of the previously described lead compound D3, which has been developed to efficiently eliminate toxic Aβ42 oligomers as a promising treatment strategy for AD. Besides the detailed in vitro characterization of RD2, we also report the results of a treatment study of APP/PS1 mice with RD2. After 28 days of treatment we observed enhancement of cognition and learning behaviour. Analysis on brain plaque load did not reveal significant changes, but a significant reduction of insoluble Aβ42. Our findings demonstrate that RD2 was significantly more efficient in Aβ oligomer elimination in vitro compared to D3. Enhanced cognition without reduction of plaque pathology in parallel suggests that synaptic malfunction due to Aβ oligomers rather than plaque pathology is decisive for disease development and progression. Thus, Aβ oligomer elimination by RD2 treatment may be also beneficial for AD patients.
000840658 536__ $$0G:(DE-HGF)POF3-553$$a553 - Physical Basis of Diseases (POF3-553)$$cPOF3-553$$fPOF III$$x0
000840658 588__ $$aDataset connected to CrossRef
000840658 7001_ $$0P:(DE-Juel1)165908$$aSchemmert, Sarah$$b1$$ufzj
000840658 7001_ $$0P:(DE-HGF)0$$aBrener, Oleksandr$$b2
000840658 7001_ $$0P:(DE-Juel1)145165$$aGremer, Lothar$$b3$$ufzj
000840658 7001_ $$0P:(DE-Juel1)162487$$aZiehm, Tamar$$b4$$ufzj
000840658 7001_ $$0P:(DE-Juel1)131709$$aTusche, Markus$$b5$$ufzj
000840658 7001_ $$0P:(DE-Juel1)162443$$aNagel-Steger, Luitgard$$b6
000840658 7001_ $$0P:(DE-HGF)0$$aKadish, Inga$$b7
000840658 7001_ $$0P:(DE-Juel1)166069$$aSchartmann, Elena$$b8$$ufzj
000840658 7001_ $$0P:(DE-Juel1)164354$$aElfgen, Anne$$b9$$ufzj
000840658 7001_ $$0P:(DE-Juel1)144626$$aJürgens, Dagmar$$b10$$ufzj
000840658 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b11$$ufzj
000840658 7001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b12$$ufzj
000840658 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b13$$eCorresponding author$$ufzj
000840658 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-017-16565-1$$gVol. 7, no. 1, p. 16275$$n1$$p16275$$tScientific reports$$v7$$x2045-2322$$y2017
000840658 8564_ $$uhttps://juser.fz-juelich.de/record/840658/files/s41598-017-16565-1.pdf$$yOpenAccess
000840658 8564_ $$uhttps://juser.fz-juelich.de/record/840658/files/s41598-017-16565-1.gif?subformat=icon$$xicon$$yOpenAccess
000840658 8564_ $$uhttps://juser.fz-juelich.de/record/840658/files/s41598-017-16565-1.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000840658 8564_ $$uhttps://juser.fz-juelich.de/record/840658/files/s41598-017-16565-1.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000840658 8564_ $$uhttps://juser.fz-juelich.de/record/840658/files/s41598-017-16565-1.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000840658 8564_ $$uhttps://juser.fz-juelich.de/record/840658/files/s41598-017-16565-1.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000840658 8767_ $$82676086065$$92017-11-17$$d2017-12-08$$eAPC$$jZahlung erfolgt$$pSREP-17-32657A
000840658 909CO $$ooai:juser.fz-juelich.de:840658$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000840658 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)165908$$aForschungszentrum Jülich$$b1$$kFZJ
000840658 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145165$$aForschungszentrum Jülich$$b3$$kFZJ
000840658 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)162487$$aForschungszentrum Jülich$$b4$$kFZJ
000840658 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131709$$aForschungszentrum Jülich$$b5$$kFZJ
000840658 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)162443$$aForschungszentrum Jülich$$b6$$kFZJ
000840658 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166069$$aForschungszentrum Jülich$$b8$$kFZJ
000840658 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)164354$$aForschungszentrum Jülich$$b9$$kFZJ
000840658 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144626$$aForschungszentrum Jülich$$b10$$kFZJ
000840658 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich$$b11$$kFZJ
000840658 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b12$$kFZJ
000840658 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b13$$kFZJ
000840658 9131_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000840658 9141_ $$y2017
000840658 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000840658 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000840658 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000840658 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record
000840658 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2015
000840658 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bSCI REP-UK : 2015
000840658 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000840658 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000840658 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000840658 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000840658 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000840658 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000840658 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences
000840658 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000840658 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000840658 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000840658 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie $$x0
000840658 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000840658 9801_ $$aAPC
000840658 9801_ $$aFullTexts
000840658 980__ $$ajournal
000840658 980__ $$aVDB
000840658 980__ $$aUNRESTRICTED
000840658 980__ $$aI:(DE-Juel1)ICS-6-20110106
000840658 980__ $$aI:(DE-Juel1)INM-4-20090406
000840658 980__ $$aAPC
000840658 981__ $$aI:(DE-Juel1)IBI-7-20200312